Irlanda - inglês - HPRA (Health Products Regulatory Authority)

rowex ltd - ivabradine - film-coated tablet - 5 milligram(s) - other cardiac preparations; ivabradine

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

rowex ltd - ivabradine - film-coated tablet - 7.5 milligram(s) - other cardiac preparations; ivabradine

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ivabradine - film-coated tablet - 5 milligram(s) - other cardiac preparations; ivabradine

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - ivabradine - film-coated tablet - 7.5 milligram(s) - other cardiac preparations; ivabradine

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - ivabradine - film-coated tablet - 5 milligram(s) - other cardiac preparations; ivabradine

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - ivabradine - film-coated tablet - 7.5 milligram(s) - other cardiac preparations; ivabradine

União Europeia - inglês - EMA (European Medicines Agency)

zentiva, k.s. - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersorin combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

União Europeia - inglês - EMA (European Medicines Agency)

accord healthcare s.l.u. - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm.ivabradine is indicated :- in adults unable to tolerate or with a contra-indication to the use of beta-blockers- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1)

Canadá - inglês - Health Canada

servier canada inc - ivabradine (ivabradine hydrochloride) - tablet - 5mg - ivabradine (ivabradine hydrochloride) 5mg - miscellaneous cardiac drugs

Canadá - inglês - Health Canada

servier canada inc - ivabradine (ivabradine hydrochloride) - tablet - 7.5mg - ivabradine (ivabradine hydrochloride) 7.5mg - miscellaneous cardiac drugs